Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

NCT05532124 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Green Cross Wellbeing